Ignite Creation Date:
2024-05-05 @ 4:35 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00277251
Status:
COMPLETED
Last Update Posted:
2017-04-11
First Post:
2005-07-07
Brief Title:
Alendronate Osteoporosis Study
Sponsor:
Boston Childrens Hospital
Organization:
Boston Childrens Hospital
Study Overview
Official Title:
Double-Blinded Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid- Associated Osteopenia and Osteoporosis
Status:
COMPLETED
Status Verified Date:
2017-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial will test the hypothesis that among 20 children and adolescents from Childrens Hospital Boston with Crohns disease ulcerative colitis systemic-onset juvenile rheumatoid arthritis juvenile dermatomyositis systemic lupus erythematosus mixed connective tissue disease and vasculitis treatment of glucocorticoid-associated osteopenia and osteoporosis with 18 months of alendronate FOSAMAX Merck Co Inc will result in greater improvement in the mean change of individual AP spine bone mineral density BMD gmcm2 determined by dual energy X-ray absorptiometry DXA than treatment with 18 months of standard of care therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None